Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Bewertung der Abgabe und Wirkung von THC-Dampfflüssigkeiten im Blutkreislauf

10. November 2026 aktualisiert von: Roswell Park Cancer Institute

Acute Effects of Sequential Nicotine Vaping on the Pharmacokinetic and Pharmacodynamic Properties of Vaped THC: A Randomized Within-Subject Crossover Study

This clinical trial assesses differences in the delivery of THC to the bloodstream depending on whether nicotine vapes are used before or after THC. While there has been much recent publicity about vaping products and concern about their safety considering their increasing use for THC administration, the THC delivery profile associated with THC liquid vaping products in human subjects is currently unknown. Importantly, how the delivery to the bloodstream of THC vaping liquids compare to delivery from smoked cannabis, which is the most used method of cannabis delivery, will serve as an important benchmark for evaluating the delivery and effects of THC vaping products, and their relative safety.

Studienübersicht

Status

Noch keine Rekrutierung

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

PRIMARY OBJECTIVES:

I. Assess pharmacokinetic (PK)/pharmacodynamic (PD) profiles of THC vaping liquids administered with co-use of vaped nicotine.

II. Outcomes of interest will be assessed overall, and according to biological sex.

SECONDARY OBJECTIVES:

I. Safety. II. Assessment of differences in puffing behaviors. III. Short-term subjective drug effects, and cognitive performance following THC use without nicotine versus (vs.) THC use with pre-nicotine use vs. THC use with post-nicotine use in current consumers of both vaped cannabis and vaped nicotine products.

OUTLINE: Participants are randomized to 1 of 3 arms.

ARM A: Participants complete 3 vaping sessions separated by 7-14 days on study:

  • VISIT 1: Participants vape placebo nicotine for 10 minutes, followed by THC for 10 minutes, and then placebo nicotine again for 10 minutes.
  • VISIT 2: Participants vape nicotine for 10 minutes, followed by THC for 10 minutes, and then placebo nicotine for 10 minutes.
  • VISIT 3: Participants vape placebo nicotine for 10 minutes, followed by THC for 10 minutes, and then nicotine for 10 minutes.

ARM B: Participants complete 3 vaping sessions separated by 7-14 days on study:

  • VISIT 1: Participants vape nicotine for 10 minutes, followed by THC for 10 minutes, and then placebo nicotine for 10 minutes.
  • VISIT 2: Participants vape placebo nicotine for 10 minutes, followed by THC for 10 minutes, and then nicotine for 10 minutes.
  • VISIT 3: Participants vape placebo nicotine for 10 minutes, followed by THC for 10 minutes, and then placebo nicotine again for 10 minutes.

ARM C: Participants complete 3 vaping sessions separated by 7-14 days on study:

  • VISIT 1: Participants vape placebo nicotine for 10 minutes, followed by THC for 10 minutes, and then nicotine for 10 minutes.
  • VISIT 2: Participants vape placebo nicotine for 10 minutes, followed by THC for 10 minutes, and then placebo nicotine again for 10 minutes.
  • VISIT 3: Participants vape nicotine for 10 minutes, followed by THC for 10 minutes, and then placebo nicotine for 10 minutes.

All participants also undergo blood sample collection throughout the trial.

After completion of study intervention, participants are followed up at 30 days.

Studientyp

Interventionell

Einschreibung (Geschätzt)

60

Phase

  • Frühphase 1

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

21 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Ja

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • Age ≥ 21 years of age; (self-reported on screening, verified at study visit).
  • Report use of commercial THC vaping cartridges for at least 3 months prior to enrollment; (self-reported).
  • Experience with THC potency at or above the study product AND experience with chasing THC with nicotine (at least monthly); (self-reported).
  • Report use of THC vaping liquids at least weekly (4x/month); (self-reported).
  • Daily use of nicotine vaping products containing >2% nicotine (>20mg/ml for at least 3 months prior to enrollment; (self-reported).
  • Report of not currently trying to become pregnant (females). Women of childbearing potential must be willing to provide a urine sample and test negative prior to receiving any study-related products/procedures.
  • Willing to complete a THC saliva test to check for recent use (NarcoCheck Ref#: NCE-STHC-1), semi-quantitative urinary THCA rapid test (NarcoCheck® THC Pre Dosage), and an illicit drug urine test (NarcoCheck® Évolutive®) during baseline testing, prior to receiving any study-related products.
  • Willing to abstain from nicotine use for 8 hours prior to each study session and abstain from cannabis use 1 day prior to each session.
  • Participant must understand the investigational nature of this study and sign an Institutional Review Board approved written informed consent form prior to receiving any study related procedure.

Exclusion Criteria:

  • Unwilling or unable to follow protocol abstinence requirements based on more than two instances of a positive THC saliva test (NarcoCheck Ref#:NCE-S THC-1).

  • Illegal or non-prescription drug use within the past 90 days. As detected by NarcoCheck® Évolutive® (detection in human urine of the 12 most currently abused drugs) at the first session and prior to receiving any study product. THC use detected by NarcoCheck® Évolutive® is permitted

  • Illegal or non-prescription drug use/alcohol substance use disorder (SUD) within the past year; (self-reported).

  • Report drinking alcohol more than 3x per week with 5 or more drinks per occasions (males) or with 4 or more drinks per occasion; (women).

  • Report of daily cigarette use; (self-reported).

  • Current or prior diagnosis of schizophrenia, bipolar disorder, or other severe psychotic mental illness; (self-reported).

  • Current or prior diagnosis of myocardial infarction, arrhythmia, or congestive heart failure (self-reported)

  • Current or prior diagnosis of chronic obstructive pulmonary disorder (COPD), cystic fibrosis, pulmonary hypertension, pulmonary edema, pulmonary embolus, or other uncontrolled respiratory conditions

  • Current cancer diagnosis.

  • Pregnant, currently trying to become pregnant, or breastfeeding (females); (self-reported; pregnancy validated on study visit by urine test).

  • Regular use of medications that contain nicotine, induce CYP2A6, stimulants, or sympatholytics (e.g., beta-blockers); (self-reported).

  • Unwilling or unable to follow protocol requirements.

  • Any condition which in the Investigator's opinion deems the participant an unsuitable candidate for participation.

  • The following special populations will be excluded:

    • Cognitively impaired adults/adults with impaired decision-making capacity
    • Individuals who are not yet adults (infants, children, teenagers)
    • Pregnant women
    • Prisoners
  • No children or person under the age of 21 will be involved in the study. While those under 21 may use cannabis smoked or vaping products, the legal age of purchasing and using those products in New York State is 21. The current legal age to purchase and use tobacco products in New York State (NYS) is 21. Thus, our provision of study product to adults aged 21 and older is in line with current NYS law.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Grundlegende Wissenschaft
  • Zuteilung: Zufällig
  • Interventionsmodell: Crossover-Aufgabe
  • Maskierung: Vervierfachen

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Arm A (placebo, THC, nicotine)

Participants complete 3 vaping sessions separated by 7-14 days on study:

  • VISIT 1: Participants vape placebo nicotine for 10 minutes, followed by THC for 10 minutes, and then placebo nicotine again for 10 minutes.
  • VISIT 2: Participants vape nicotine for 10 minutes, followed by THC for 10 minutes, and then placebo nicotine for 10 minutes.
  • VISIT 3: Participants vape placebo nicotine for 10 minutes, followed by THC for 10 minutes, and then nicotine for 10 minutes.

All participants also undergo blood sample collection throughout the trial.

Ancillary studies

Undergo blood collection

Andere Namen:
  • Biologische Probensammlung
  • Bioprobe gesammelt
  • Probenentnahme

Vape THC

Andere Namen:
  • Cannabis sativa
  • Cannabis sativa Blütenspitze
  • Cannabis sativa Subsp. Blühender Spitzenextrakt
  • Cannabis sativa Top

Vape active nicotine

Andere Namen:
  • (-)-Nikotin
  • Netzwerkkarte

Vape placebo nicotine

Experimental: Arm B (placebo, THC, nicotine)

Participants complete 3 vaping sessions separated by 7-14 days on study:

  • VISIT 1: Participants vape nicotine for 10 minutes, followed by THC for 10 minutes, and then placebo nicotine for 10 minutes.
  • VISIT 2: Participants vape placebo nicotine for 10 minutes, followed by THC for 10 minutes, and then nicotine for 10 minutes.
  • VISIT 3: Participants vape placebo nicotine for 10 minutes, followed by THC for 10 minutes, and then placebo nicotine again for 10 minutes.

All participants also undergo blood sample collection throughout the trial.

Ancillary studies

Undergo blood collection

Andere Namen:
  • Biologische Probensammlung
  • Bioprobe gesammelt
  • Probenentnahme

Vape THC

Andere Namen:
  • Cannabis sativa
  • Cannabis sativa Blütenspitze
  • Cannabis sativa Subsp. Blühender Spitzenextrakt
  • Cannabis sativa Top

Vape active nicotine

Andere Namen:
  • (-)-Nikotin
  • Netzwerkkarte

Vape placebo nicotine

Experimental: Arm C (placebo, THC, nicotine)

Participants complete 3 vaping sessions separated by 7-14 days on study:

  • VISIT 1: Participants vape placebo nicotine for 10 minutes, followed by THC for 10 minutes, and then nicotine for 10 minutes.
  • VISIT 2: Participants vape placebo nicotine for 10 minutes, followed by THC for 10 minutes, and then placebo nicotine again for 10 minutes.
  • VISIT 3: Participants vape nicotine for 10 minutes, followed by THC for 10 minutes, and then placebo nicotine for 10 minutes.

All participants also undergo blood sample collection throughout the trial.

Ancillary studies

Undergo blood collection

Andere Namen:
  • Biologische Probensammlung
  • Bioprobe gesammelt
  • Probenentnahme

Vape THC

Andere Namen:
  • Cannabis sativa
  • Cannabis sativa Blütenspitze
  • Cannabis sativa Subsp. Blühender Spitzenextrakt
  • Cannabis sativa Top

Vape active nicotine

Andere Namen:
  • (-)-Nikotin
  • Netzwerkkarte

Vape placebo nicotine

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Maximum concentration of THC in plasma (Cmax)
Zeitfenster: Up to 21 days

Pharmacokinetics (PK) profiles of THC in plasma will be determined using a visual plot of plasma THC concentrations by time. Parameters will be derived using non-compartmental analysis in Phoenix WinNonlin and adjusted for baseline THC levels. Will be summarized by nicotine status using the appropriate descriptive statistics and graphical summaries.

Up to 21 days
Time to maximum concentration of THC in plasma (Tmax)
Zeitfenster: Up to 21 days

Blood samples will be collected for plasma levels of THC. Parameters will be derived using linear mixed models.

Up to 21 days
Area under the plasma concentration-time curve from 0-120 minutes (AUC0-120)
Zeitfenster: Up to 21 days

Blood samples will be collected for plasma levels of THC. Parameters will be derived using linear mixed models

Up to 21 days

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Incidence of adverse events (AEs)
Zeitfenster: Up to 30 days after completion of study intervention

AEs will be summarized by nicotine condition and grade using frequencies and relative frequencies. Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 will be utilized for AE reporting.

Up to 30 days after completion of study intervention
Puffing behaviors
Zeitfenster: Up to 21 days

puff duration

Up to 21 days
Puffing behaviors
Zeitfenster: Up to 21 days

puff number

Up to 21 days
Short-term drug effects
Zeitfenster: Up to 21 days

The short-term drug effects (Drug Effects Questionnaire [DEQ), The DEQ rates sixteen component items using a visual analog scale (0-100) to examine drug effects pre- and post-use

Up to 21 days
Marijuana Withdrawal Checklist [MWC)
Zeitfenster: Up to 21 days

The Marijuana Withdrawal Questionnaire Total Score includes items assessing anxiety, depression, irritability, appetite, aggression/anger, sleep disturbance, somatic disturbances, and craving to use marijuana. The potential range of this total score is from "0" = no withdrawal symptoms to "47" = maximally high levels of withdrawal

Up to 21 days
Digit Symbol Substitution Task (DSST)
Zeitfenster: Up to 21 days

An assessment of cognitive dysfunction that test ability to complete daily tasks

Up to 21 days
Paced Auditory Serial Addition Task (PASET)
Zeitfenster: Up to 21 days

Measures of working memory and concentration .

Up to 21 days
Tobacco Craving Questionnaire (Short Form)
Zeitfenster: Up to 21 days

Self reported 47-item questionnaire that assesses tobacco craving. Items are rated on a Likert-type scale from 1 (strongly disagree) to 7 (strongly agree). Factor scores for each participant are obtained by summing the three items in each factor scale, yielding a score ranging from 3 to 21.

Up to 21 days

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Mitarbeiter

Ermittler

  • Hauptermittler: Danielle M Smith, Roswell Park Cancer Institute

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Geschätzt)

15. Dezember 2026

Primärer Abschluss (Geschätzt)

1. Dezember 2028

Studienabschluss (Geschätzt)

1. Dezember 2029

Studienanmeldedaten

Zuerst eingereicht

7. März 2024

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

20. März 2024

Zuerst gepostet (Tatsächlich)

27. März 2024

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

16. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

10. November 2026

Zuletzt verifiziert

1. November 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • I-3597023
  • R01DA057228 (US NIH Stipendium/Vertrag)
  • I-3597023 (Andere Kennung: Roswell Park Cancer Institute)
  • NCI-2024-01556 (Registrierungskennung: CTRP (Clinical Trial Reporting Program))

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Ja

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Produkt, das in den USA hergestellt und aus den USA exportiert wird

Ja

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .